Clinical Trial Update: Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD). [Phase 2]

View source ↗

Summary

A completed Phase 2 study assessed the safety, tolerability, and PK/PD of Ambrx's compound in young adults with childhood-onset growth hormone deficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• Ambrx growth hormone deficiency compound

Snippet

Sponsor: Ambrx, Inc. | Conditions: Growth Hormone Deficiency | Phase 2 | Status: COMPLETED